Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Cytokine Response Clear all
Recruiting Early Phase 1 Interventional

Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

NCT05306080
View directory record Official record
Conditions
CRS - Cytokine Release Syndrome, HLH
Interventions
Tadekinig alfa (IL-18BP)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed No phase listed Observational

Cardiopulmonary Bypass and Inflammatory Response

NCT00167349
View directory record Official record
Conditions
Thoracic Surgery, Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 18, 2026, 4:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
View directory record Official record
Conditions
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
Anakinra (Kineret®)
Drug
Lead sponsor
Kevin McNerney
Other
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

NCT04271735
View directory record Official record
Conditions
Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
Interventions
Niagen, Placebo
Dietary Supplement · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacology of Exenatide in Pediatric Sepsis

NCT01573806
View directory record Official record
Conditions
Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions
Exenatide, Exenatide vehicle
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Chronic Alcohol, Stress Inflammatory Response and Relapse Risk

NCT02193204
View directory record Official record
Conditions
Alcohol Dependence, Depressive Symptomatology
Interventions
Personal Stress Imagery, Neutral Imagery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 18, 2026, 4:15 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Baricitinib for COVID-19

NCT04340232
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigating Severe Acute Respiratory Syndrome (SARS)

NCT00066209
View directory record Official record
Conditions
SARS Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 18, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078
View directory record Official record
Conditions
Cytokine Storm, SARS-CoV-2
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

G-CSF to Treat Crohn's Disease

NCT00025805
View directory record Official record
Conditions
Crohn's Disease
Interventions
G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

NCT04362813
View directory record Official record
Conditions
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 18, 2026, 4:15 AM EDT
Completed No phase listed Observational

Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO

NCT00371241
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome, Diaphragmatic Hernia, Meconium Aspiration, Sepsis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 30 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 18, 2026, 4:15 AM EDT
Not listed No phase listed Observational

Translational Approaches to Septic Cardiomyopathy

NCT03252613
View directory record Official record
Conditions
Cardiomyopathies, Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Samuel Brown
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Stanford, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

NCT00808665
View directory record Official record
Conditions
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions
Dexmedetomidine, 0.9% Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Not applicable Interventional

UNITE Study (UMN-SW) for COVID-19

NCT04854798
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic Ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Burnsville, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

NCT01949896
View directory record Official record
Conditions
Transfusions
Interventions
NPO, Control group: continue feedings
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
3 Days to 6 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated No phase listed Observational

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

NCT03557749
View directory record Official record
Conditions
Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions
Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product
Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Not applicable Interventional

Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery

NCT00639795
View directory record Official record
Conditions
Pain
Interventions
Thoracic Paravertebral Nerve Block
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 18, 2026, 4:15 AM EDT